Indications |
Oral HIV infection Adult: As tablet/capsule: ≥60 kg: 400 mg daily as a single dose or in 2 divided doses; <60 kg: 250 mg daily as a single dose or in 2 divided doses. Child: 2 wk-8 mth: 100 mg/m2 bid; >8 mth: 120 mg/m2 bid. For chewable or dispersible tablets: >3 mth: 240 mg/m2 daily or 180 mg/m2 daily if given with zidovudine; doses may be given in 1-2 divided doses. For enteric-coated capsules: >6 yr: 240 mg/m2 daily or 180 mg/m2 daily if given with zidovudine. Renal impairment: Dosage adjustments based on weight and creatinine clearance. Dose should preferably be admin after dialysis.
Special Populations: Reduce dose in patients with renal or hepatic impairment. |
||||||||
Contraindications |
Hypersensitivity; lactation. | ||||||||
Warnings / Precautions |
History of pancreatitis and liver disease; pregnancy; impaired hepatic and renal function; peripheral neuropathy; hyperuricaemia. Half-yrly dilated retinal examinations are recommended. May be associated with the development of non-cirrhotic portal hypertension; monitor patients for the development of portal hypertension and oesophageal varices. Suspend use in patients with suspected pancreatitis and discontinue use in patients with confirmed pancreatitis. Suspend use in patients who develop clinical symptoms or signs with or without laboratory findings of lactic acidosis and severe hepatomegaly with steatosis. Consider usage discontinuation or interruption in patients with worsening liver disease. Patients may develop peripheral neuropathy, retinal changes and optic neuritis, immune reconstitution syndrome and redistribution/accumulation of body fat. | ||||||||
Adverse Reactions |
Pancreatitis; peripheral neuropathy; diarrhoea, nausea, vomiting, abdominal pain; headache, fatigue, rash, hyperuricaemia; hepatic failure; retinal depigmentation, neuritis. | ||||||||
Overdose Reactions |
Symptoms: pancreatitis, peripheral neuropathy, hyperuricemia and hepatic dysfunction. Management: There is no known antidote. Empty stomach by inducing emesis or by gastric lavage. Treatment is supportive and symptomatic with careful monitoring of the patient. Haemodialysis may remove some of the drug while peritoneal dialysis is unlikely to be useful. | ||||||||
Drug Interactions |
Increased effect with allopurinol and ganciclovir; hydroxyurea; increased toxicity with ribavirin or tenofovir. Decreased effects of quinolones, tetracyclines, indinavir. Increased risk of pancreatitis when used with pentamidine, stavudine or co-trimoxazole. Increased risk of liver toxicity when used with other antiretroviral agens, hydroxyurea or ribavirin. See Below for More didanosine Drug Interactions |
||||||||
Food Interactions |
Effect decreased by food. | ||||||||
Mechanism of Actions |
Didanosine is a nucleoside reverse transcriptase inhibitor that inhibits DNA synthesis of retroviruses by competitive inhibition of reverse transcriptase and incorporation into viral DNA. Absorption: Rapidly hydrolysed in the gastric acid. Bioavailability ranges from 20-40%. Distribution: Plasma protein binding: <5%. Metabolism: Metabolised intracellularly to the active antiviral metabolite dideoxyadenosine triphosphate. Excretion: Elimination half-life: About 1.5 hr. |
||||||||
Administration |
Should be taken on an empty stomach. (Take on an empty stomach ½ hr before or 2 hr after meals.) |
||||||||
Storage Conditions |
Oral: Store at 15-30°C. | ||||||||
ATC Classification |
J05AF02 - didanosine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections. | ||||||||
Storage |
Oral: Store at 15-30°C. | ||||||||
Available As |
|
Didanosine
Post Review about Didanosine Click here to cancel reply.
Didanosine Containing Brands
Didanosine is used in following diseases
Drug - Drug Interactions of Didanosine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.